Evaluating Pathological Biomarkers to Avoid Diagnostic Delays
Jonathan Schott, MD, describes the use of structural imaging in Alzheimer’s disease and highlights the different presentations of atrophy in typical and atypical presentations. He then discusses PET imaging and CSF biomarkers in Alzheimer’s disease before examining the biomarker results from the patient case, alongside Giovanni Frisoni.
Key Learning Objectives for Biogen’s EAN 2020 Symposium:
- Understand the value of an early diagnosis of Alzheimer’s disease
- Gain insights on how comprehensive cognitive assessment tools and fluid and imaging biomarkers can be used to achieve an accurate and timely diagnosis of mild cognitive impairment due to Alzheimer’s disease
- Assess the current healthcare system readiness for a paradigm shift to early diagnosis
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.